Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14876084 | 0.94 | KMT2A (0.51) | HPGDALDH1A1KDM4EKMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL14876520 | 0.93 | KMT2A (0.50) | HPGDALDH1A1KDM4EKMT2AALOX15 | |
| SCHEMBL14881179 | 0.92 | ACLY (0.43) | HPGDALDH1A1KDM4EKMT2AALOX15 | |
| SCHEMBL14882792 | 0.91 | GRM4 (0.43) | HPGDALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL14882734 | 0.91 | LIMK2 (0.43) | HPGDALDH1A1KDM4EKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL14876128 | 0.91 | ACLY (0.43) | HPGDALDH1A1KDM4EKMT2AALOX15 | |
| Hydrochloric Acid SCHEMBL14876559 | 0.90 | LIMK2 (0.43) | HPGDALDH1A1KDM4EKMT2AMAPT | |
| Hydrochloric Acid SCHEMBL14875709 | 0.90 | GRM4 (0.43) | HPGDALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL14882737 | 0.88 | GRM4 (0.42) | KMT2AMEN1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL14875917 | 0.87 | GRM4 (0.42) | KMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| CN-103958521-B | Pyrimidin-4-one derivatives and their use in the treatment, alleviation or prevention of viral diseases | 弗·哈夫曼-拉罗切有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| EP-2794616-B1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2794616-B1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| CN-103958475-B | Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| EP-2794616-A1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-2776396-A2 | HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057253-A1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013057251-A2 | HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | TPMT, TYMP, HPRT1 | HPGD 1380/4885ALDH1A1 609/4885KDM4E 3487/4885 |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | HPGD 3111/4885ALDH1A1 464/4885KDM4E 3351/4885 |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | ALAD, CYP27A1, FAH | HPGD 682/4885ALDH1A1 956/4885KDM4E 3498/4885 |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | FAH, SLC10A1, OAT | HPGD 487/4885ALDH1A1 965/4885KDM4E 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.